Table 1.

Model Input Parameters for Analysis of Cardiovascular Disease Risk in People Living With Human Immunodeficiency Virus in the United States

Variable	Base Case Value				Reference
Cohort characteristics
Age, y (SD)	36 (0)				[15]
Distribution of initial CD4 (mean cells/µL) ± SD	751 (267)				[30]
HIV RNA distribution after acute infection, %
>100000 copies/mL	25				Derived from [33]
30001–100000 copies/mL	42
10001–30000 copies/mL	21
3001–10000 copies/mL	12
Overall first-line antiretroviral therapy efficacy
HIV RNA suppressed at 6 months, %	91				[32]
Smoking prevalence, %
Age	US General Population (M/F)			Derived from [17]
≤50 years	27.7/21.4
>50 years	17.6/14.9
	HIV-Uninfected, at High Risk for HIV and PLWH (M/F)
≤50 years	43.0/36.3
>50 years	37.2/31.6
CVD-attributable mortality, % monthly M/F
Age (y)	All cohorts				Derived from [21, 22]
20–29	0.11/0.07
30–39	0.15/0.09
40–49	0.24/0.13
50–59	0.21/0.14
60–69	0.24/0.22
70+	0.46/0.65
CVD prevalence, % at initiation (M/F)
Age (y)	General Population a	HIV-Uninfected, at High Risk for HIV b			PLWHb
20–29	0.6/0.5	0.7/0.6			1.2/1.0
30–39	1.5/1.3	1.7/1.4			2.9/2.4
40–49	3.2/2.7	3.5/2.9			6.1/4.9
50–59	8.4/5.9	10.1/6.7			17.2/11.1
60–69	15.8/8.9	19.0/10.1			28.1/14.4
70+	28.4/17.6	34.1/20.0			56.2/30.1
Estimated CVD incidence, cases per 10000 people per month (M/F)
Age (y)	General Population	HIV-Uninfected, at High Risk for HIV			PLWH
20–29	0.5/0.4	0.6/0.5			1.1/0.8
30–39	1.4/1.1	1.5/1.2			2.7/2.1
40–49	3.0/2.4	3.4/2.6			5.9/4.6
50–59	8.1/5.5	9.8/6.2			17.2/10.9
60–69	15.1/8.4	18.1/9.6			31.9/16.9
70+	36.4/22.9	43.7/26.0			76.8/45.7

All values are reported as male/female.

Abbreviations: CVD, cardiovascular disease; HIV; human immunodeficiency virus; PLWH; people living with HIV; SD, standard deviation.

^aDerived from National Health Interview Survey using positive predictive values (see Methods and Supplementary Appendix).

^bDerived using CEPAC model as described in the Methods.